The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has milder presentation in children than in adults, mostly requiring only supportive therapy. The immunopathogenic course of COVID-19 can be divided in two distinct but overlapping phases: the first triggered by the virus itself and the second one by the host immune response (cytokine storm). Respiratory failure or systemic involvement as Multisystem Inflammatory Syndrome in Children (MIS-C) requiring intensive care are described only in a small portion of infected children. Less severe lung injury in children could be explained by qualitative and quantitative differences in age-related immune response. Evidence on the best therapeutic approach for COVID-19 lung disease in children is lacking. Currently, the approach is mainly conservative and based on supportive therapy. However, in hospitalized children with critical illness and worsening lung function, antiviral therapy with remdesivir and immunomodulant treatment could be considered the "therapeutic pillars."

Therapeutic Strategies for COVID-19 Lung Disease in Children / E. Gatti, M. Piotto, M. Lelii, M. Pensabene, B. Madini, L. Cerrato, V. Hassan, S. Aliberti, S. Bosis, P. Marchisio, M.F. Patria. - In: FRONTIERS IN PEDIATRICS. - ISSN 2296-2360. - 10:(2022 May 07), pp. 829521.1-829521.10. [10.3389/fped.2022.829521]

Therapeutic Strategies for COVID-19 Lung Disease in Children

E. Gatti
Primo
;
M. Piotto
Secondo
;
M. Lelii;M. Pensabene;B. Madini;L. Cerrato;V. Hassan;S. Aliberti;S. Bosis;P. Marchisio
Penultimo
;
2022

Abstract

The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has milder presentation in children than in adults, mostly requiring only supportive therapy. The immunopathogenic course of COVID-19 can be divided in two distinct but overlapping phases: the first triggered by the virus itself and the second one by the host immune response (cytokine storm). Respiratory failure or systemic involvement as Multisystem Inflammatory Syndrome in Children (MIS-C) requiring intensive care are described only in a small portion of infected children. Less severe lung injury in children could be explained by qualitative and quantitative differences in age-related immune response. Evidence on the best therapeutic approach for COVID-19 lung disease in children is lacking. Currently, the approach is mainly conservative and based on supportive therapy. However, in hospitalized children with critical illness and worsening lung function, antiviral therapy with remdesivir and immunomodulant treatment could be considered the "therapeutic pillars."
COVID-19; antiviral therapy; children; immunomodulant treatment; lung disease; respiratory support;
Settore MED/38 - Pediatria Generale e Specialistica
Article (author)
File in questo prodotto:
File Dimensione Formato  
GATTI E therapeutic strategies COVID-19 2022.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 486.57 kB
Formato Adobe PDF
486.57 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/935715
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact